The healthcare sector, with its potential for long-term growth opportunities, has been attracting investors worldwide. One such company, Sorrento Therapeutics, is a biopharmaceutical company that develops innovative therapies for unmet medical needs. However, investing in the healthcare sector comes with its own set of challenges and risks.
Evaluating Investment Factors
Prospective investors must evaluate various factors before making a purchase decision, including financial performance, the pipeline of products under development, the regulatory environment, the competition landscape, and other key variables. The healthcare sector is subject to fluctuations based on external events such as global pandemics or political actions. For instance, StockNews has given Sorrento Therapeutics a “hold” rating, reflecting their view that it may not be an appropriate investment choice for all investors at this time.
Opportunities in the Asian Market
Hong Kong is the premier biotech fundraising capital in Asia, and the Covid-19 pandemic has accelerated the usage of technology in healthcare sectors. The Hong Kong Trade Development Council (HKTDC) is providing a platform to stimulate business connectivity through the second “International Healthcare Week” (IHW). The IHW will bring together over ten health-related events in Hong Kong, including the third Asia Summit on Global Health (ASGH) and the 14th edition of the HKTDC Hong Kong International Medical and Healthcare Fair.
Technology and AI in Healthcare
Dr Gerald Chan, co-founder of health-tech investor Morningside Group, will speak at ASGH 2023 and share his insights on how technology and AI can disrupt the status quo to deliver better and faster healthcare at a lower cost. Morningside has pivoted from developing novel therapeutics to developing technologies to reconfigure the delivery of healthcare, with AI being an indispensable part of the future of healthcare.
CK Life Sciences and the Future of Healthcare
CK Life Sciences, a diversified life sciences company in Hong Kong billionaire Li Ka-shing’s CK Hutchison Group, is engaged in the business of research and development, manufacturing, commercialization, and investment in products in categories including nutraceuticals, pharmaceuticals, diagnostics, and agriculture-related. CK Life Sciences’ current major R&D focus is on cancer vaccines, including collaboration with Shenzhen- headquartered company Xtalpi to develop a novel AI-empowered cancer vaccine R&D platform. Dr Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, opined that the pandemic accelerated the adoption of advanced data analytics, AI, and Digital Health in the healthcare industry. Dr Toh also noted that the
pandemic had led to consumers placing increasing priority on self-care and disease prevention.
